MedScience Ventures, LLC. (MSV) is a U.S., Europe, and Asia-based fund management company focused on emerging life science and medical technologies.

MSV seeks to partner with innovative, emerging companies to provide consulting services, obtain exclusive license rights in specific markets, and evaluate making equity investments. 

Managing Partners

Stefano Ciampolini is a founder of MedScience Ventures (MSV) and a Member of the General Partner. Mr. Ciampolini is an Adjunct Professor of Imperial College Business School in London and Entrepreneur-in-Residence. He is a healthcare entrepreneur and co-founder of Healthcare Capital Partners, a London-based private equity and corporate finance advisory boutique firm specialized in life sciences and healthcare ventures. He started his professional career with his family's group of companies, which included private clinics and diagnostic equipment manufacturing in Italy, France and the United States. He joined Arthur Andersen in London in 1996, where he was a member of its healthcare corporate finance team. In 1999, he founded NephroNet, a chain of independent dialysis centers, which was later acquired by Baxter Inc. As part of his investment activities, Mr. Ciampolini is a founder, board member and investor in several healthcare ventures and private equity funds focusing on healthcare investments in Europe and the United States. He is Chief Executive Officer and founder of Renal Services, a UK dialysis services company, a founder and board member of Pure Life Renal, a U.S. dialysis services company, a founder and board member of biofficient.com, a bio-procurement platform, and a founder and board member of UV Light Care, a U.S. medical devices company. Mr. Ciampolini earned an MBA from Imperial College Business School in London in 1994 and holds a degree in economics from Kingston University in Surrey.

Stefano Ciampolini
Managing Partner

Sherwyn Hung is a founder of MedScience Ventures (MSV) and a Member of the General Partner. For 27 years, Mr. Hung has worked with U.S. and European multinational pharmaceutical and life science companies. Mr. Hung is currently responsible for PUMC Pharmaceutical’s general management duties. From 1995 to 1999, Mr. Hung served as Chief Operating Officer of National Medical Care/Asia Renal Care, which pioneered the development of organ procurement programs in the Asia Pacific region. During this time, he oversaw the adoption of KDOQI guidelines for CQI throughout Asia Renal Care’s dialysis centers in China, Taiwan, Korea, Singapore, Thailand, and the Philippines. From 1991 to 1994, Mr. Hung served as General Manager of Sandoz Hong Kong and China, and Regional Marketing Director of Sandoz Asia Pacific. During this time, he launched the company’s first organ procurement programs in the Asia Pacific region. Mr. Hung also served as General Manager of SmithKline Beecham Taiwan as Head of Abbott Laboratories' Hospital Division, and as Sales Manager for Eli Lilly Taiwan. Mr. Hung holds an MBA from the Kelley School of Business at Indiana University Bloomington.

Sherwyn Hung
Managing Partner

Christopher Ford is a founder of MedScience Ventures (MSV) and a Member of the General Partner. Since 1999, Mr. Ford has served as Chairman (Ret.) and Co-Founder of American Renal Associates Holdings, Inc. (NYSE: ARA) – one of the largest dialysis providers in the United States and offers an alternative to traditional large dialysis chain ownership. Mr. Ford co-founded ARA in August 1999 with two colleagues from Fresenius Medical Care, the world's largest dialysis company. As of 2016, ARA owns and operates over 200 outpatient dialysis clinics in 25 states and the District of Columbia, treats over 13,000 patients, and has over 4,000 employees. Mr. Ford also formerly served as President of Fresenius's International Services Division. During his tenure as President of Fresenius’s International Services Division, he grew the division from a small presence in Spain and Portugal to a worldwide organization, providing care for 10,000 chronic dialysis patients in fourteen countries. Prior to serving as President of Fresenius’s International Services Division, Mr. Ford was responsible for all of Fresenius’s U.S. operations and served as Senior Vice President of Operations for the U.S. Dialysis Services Division. He has worked in the dialysis services industry since 1971, and during his career (which spans over forty years) he has contributed to the build-out of the U.S. dialysis market from its infancy in the 1970's to a $19 billion healthcare business today. Mr. Ford received his BS degree in Business Administration from Northeastern University in Boston, MA. 

Christopher Ford
Managing Partner

Nick Wu is a Member of the MedScience Ventures (MSV) General Partner and a healthcare and medical device professional who has more than 30 years of experience serving as a member of senior management for leading multi-national medical device and healthcare companies. Mr. Wu has extensive experience in international medical device sales and marketing management and has a robust international medical device professional network, including networks in the Greater China and Asia Pacific regions. In particular, Mr. Wu has experience in medical device sales and marketing and healthcare management in the hemodialysis, surgical, blood banking, dental, cardiology, and radiology fields. He also has experience in nursing home management and medical device manufacturing. Mr. Wu began his professional career with B. Braun in Taiwan, where he dealt in surgical instruments, sutures, orthopedic implants and medical disposables, and later joined Terumo, a large medical device company, as Taiwan Country Manager. In 2000, he joined Gambro, a medical technology company, as General Manager of Gambro Taiwan and President and Chief Executive Officer of Gambro Asia-Pacific. Mr. Wu has served as President of Quality System Control Inc., a company engaged in the business of medical device and automotive parts manufacturing, since 2015. Mr. Wu received an EMBA from the National Taiwan University of Science and Technology and graduated from Taipei Medical University in 1978 with a concentration in medical technology.

Nick Wu
Managing Partner

Bret Siarkowski is a founder of MedScience Ventures (MSV) and a Member of the General Partner. Mr. Siarkowski is a seasoned entrepreneur with over 20 years of experience initiating and leading technology companies in the design and application of innovative market-demanded solutions, as well as creating new markets. His extensive experience spans the mobile, gaming, healthcare, software, semiconductor and electronics industries. Mr. Siarkowski is a Limited Partner at Kodiak Venture Partners, an angel investor, and serves on the board of advisors for several technology companies. Mr. Siarkowski holds a BSEE from Northeastern University in Boston, MA and an MSEE from the University of Southern California in Los Angeles, CA. He also is the holder of several patents that cover both software and hardware industries.

Bret Siarkowski
Managing Partner

Lidong Zhang is a Member of the MedScience Ventures (MSV) General Partner and a professional in the pharmaceutical industry with more than 28 years of experience. Mr. Zhang has extensive experience in, among other things, research and development, sales, and management for well-known national and international pharmaceutical, life sciences, medical information, and medical device companies. Since March 2014, Mr. Zhang has served as the Chief Executive Officer of Milestone China Co., Ltd; a partner of Hinacom Software & Technology, Ltd; and the chairman of the board of, and an investor in, Solee (Wuhan) Science & Technology Co., Ltd. Mr. Zhang served China National Pharmaceutical Group (Sinopharm), the largest state-owned pharmaceutical company in China, for 14 years from July 1999, and was responsible for overseeing Sinopharm’s subsidiaries, including by serving as vice president of China National Bio-tech Group, the largest vaccine manufacture and supplier in China, from April 2010 to December 2013; president of China National Medicines Corporation Ltd; chairman of National Medicines Prospect Dentech (Beijing) Co. Ltd from April 2008 to March 2009; president of China National Pharmaceutical Logistics Co. Ltd and China National Medicines Corporation Ltd from July 2008 to February 2009; and chairman of Beijing Drug Store Chain Co., Ltd from January 2005 to March 2007. During his tenure at Sinopharm, Mr. Zhang gained experience in conducting initial public offerings. Mr. Zhang also served as a business manager at Beijing Pharmacy and Healthcare Import and Export Co. from March 1996 to July 1999; a national sales manager at Sandoz Pharmaceutical (China) from February 1993 to March 1996; and a sales manager at Guang Zhou Bai Yun Shan Pharmaceutical Co., Ltd from July 1988 to February 1993. Mr. Zhang received an EMBA from Tsinghua University in 2007 and graduated from Beijing University Medical School with a concentration in pharmaceutical chemistry in 1988.

Lidong Zhang
Managing Partner

Associates & Staff

Ashley Ford
Managing Director

Yang Gao
Business Development Director

Yi Liu
Business Development Manager

Casey Ford
Managing Director

Jason Hung
Business Development Manager

 

Chiwen Hung
Managing Director

Jeffrey Hung
Business Development Manager

 

Gus Adapon
Director of Investor Relations

David Stanton
Operations Manager

Andy Chen
Business Development Manager